BCL6 and neoplasm: This population included a strong proportion of tumor antigen-specific T cells and of BCL6+CD122+ T cells that might share functional properties with stem-like CD8+ T cells and could explain why the Vox+anti-PD-1 antibody combination offers protection against tumor rechallenge.